463,951 Shares in Dynavax Technologies Co. (DVAX) Acquired by Renaissance Technologies LLC
Renaissance Technologies LLC bought a new position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 463,951 shares of the biopharmaceutical company’s stock, valued at approximately $1,833,000. Renaissance Technologies LLC owned approximately 1.20% of Dynavax Technologies as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the stock. Rathbone Brothers plc acquired a new stake in shares of Dynavax Technologies during the third quarter worth approximately $105,000. Two Sigma Securities LLC acquired a new stake in shares of Dynavax Technologies during the third quarter worth approximately $115,000. Wells Fargo & Company MN boosted its stake in shares of Dynavax Technologies by 4.1% in the third quarter. Wells Fargo & Company MN now owns 14,433 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 563 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Dynavax Technologies during the fourth quarter worth approximately $317,000. Finally, Baker BROS. Advisors LP acquired a new stake in shares of Dynavax Technologies during the third quarter worth approximately $787,000. 84.61% of the stock is owned by institutional investors and hedge funds.
Shares of Dynavax Technologies Co. (NASDAQ:DVAX) opened at 5.60 on Friday. The stock’s market capitalization is $248.37 million. The firm’s 50-day moving average is $5.76 and its 200-day moving average is $6.02. Dynavax Technologies Co. has a one year low of $3.20 and a one year high of $23.62.
Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Monday, March 13th. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.29. The company earned $7.30 million during the quarter, compared to analyst estimates of $2.90 million. Dynavax Technologies had a negative net margin of 2,650.25% and a negative return on equity of 78.57%. The firm’s revenue was up 965.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.70) EPS. On average, analysts expect that Dynavax Technologies Co. will post ($1.57) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “463,951 Shares in Dynavax Technologies Co. (DVAX) Acquired by Renaissance Technologies LLC” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/04/21/463951-shares-in-dynavax-technologies-co-dvax-acquired-by-renaissance-technologies-llc.html.
Separately, Cowen and Company reaffirmed a “buy” rating and set a $45.00 target price on shares of Dynavax Technologies in a report on Friday, January 6th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $20.80.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Stock Ratings for Dynavax Technologies Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Co. and related stocks with our FREE daily email newsletter.